Search hospitals > Delaware > Newark
Helen F. Graham Cancer Center
Claim this profileNewark, Delaware 19713
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
345 reported clinical trials
8 medical researchers
Summary
Helen F. Graham Cancer Center is a medical facility located in Newark, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Ovarian Cancer and other specialties. Helen F. Graham Cancer Center is involved with conducting 345 clinical trials across 446 conditions. There are 8 research doctors associated with this hospital, such as Gregory A. Masters, Timothy D. Moore, Aine E. Clements, and Anitha S. Nallari.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Gregory A. MastersHelen F Graham Cancer Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
133 reported clinical trials
213 drugs studied
Timothy D. MooreThe Mark H Zangmeister Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
126 reported clinical trials
208 drugs studied
Aine E. ClementsOhioHealth Mansfield Hospital2 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
7 reported clinical trials
32 drugs studied
Anitha S. NallariColumbus Oncology and Hematology Associates2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
4 reported clinical trials
10 drugs studied
Clinical Trials running at Helen F. Graham Cancer Center
Lung Cancer
Breast Cancer
Prostate Cancer
Breast cancer
Cancer
Skin Cancer
Colorectal Cancer
Esophageal cancer
Cervical Cancer
Kidney Cancer
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Helen F. Graham Cancer Center?
Helen F. Graham Cancer Center is a medical facility located in Newark, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Ovarian Cancer and other specialties. Helen F. Graham Cancer Center is involved with conducting 345 clinical trials across 446 conditions. There are 8 research doctors associated with this hospital, such as Gregory A. Masters, Timothy D. Moore, Aine E. Clements, and Anitha S. Nallari.
Where is Helen F. Graham Cancer Center located?
The Helen F. Graham Cancer Center & Research Institute is situated on the Christiana Hospital campus, located at 4701 Ogletown-Stanton Road, Newark, DE 19713. For directions, take I-95 to Exit 1B, follow DE-896 N towards Newark for about 2 miles, then turn left onto DE-4 E/Ogletown Stanton Rd. Continue for approximately 1 mile to find the hospital campus on your right.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the Helen F. Graham Cancer Center:
- Contact your Patient Access Coordinator (PAC) through your doctor's office or via the Find a Doctor page.
- For insurance inquiries, call the Cancer Care Management Department at 302-623-4700.
- Location: 4701 Ogletown-Stanton Road, Newark, DE 19713.
What insurance does Helen F. Graham Cancer Center accept?
The Helen F. Graham Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna HMO/POS, Amerihealth HMO/Keystone, Humana Medicare Advantage, BCBS – DE/MD/Out of Area, Cigna HMO/PPO, Medicaid (DE only), and United Healthcare. Patients are advised to verify coverage and any required authorizations or referrals directly with their insurance provider.
What awards or recognition has Helen F. Graham Cancer Center received?
The Helen F. Graham Cancer Center & Research Institute, located in Newark, Delaware, is renowned for its comprehensive multidisciplinary cancer care, serving over 219,000 patients annually. As a National Cancer Institute selected Community Cancer Center, it offers advanced medical, surgical, and radiation procedures, alongside diagnostic services. The center collaborates with prestigious institutions such as The Wistar Institute, the University of Delaware, Nemours / A.I. du Pont Hospital for Children, Rice University / BioScience Research Collaborative, and the Delaware Biotechnology Institute for cutting-edge cancer research.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.